Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoronaVac Bridging Study in Children 3-11 Years
NCT05137418Phase 3Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Nov 2021
- Primary completion
- Jan 2023
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 3, open-label trial of coronavac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Geometric Mean Titer of Neutralizing Antibodies. Started Nov 2021; status: completed.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05137418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137418.